ArticleTranslational cancer research2025
CNTN1 promotes cell proliferation and metastasis in ovarian cancer through PSEN1.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer.Cell division · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer (OC) is a commonly occurring malignant tumor in women with a high mortality rate. Early detection remains challenging, and therapeutic options for advanced OC are severely limited. Therefore, there is an urgent need to identify novel biomarkers and therapeutic targets to improve outcomes for patients. Contactin-1 (CNTN1), a member of the immunoglobulin superfamily, functions as a modulator of cancer progression, yet its specific role in OC remains undefined. The present study aimed to investigate the clinical significance and regulatory role of CNTN1 in OC proliferation and metastasis. Methods: This study examined CNTN1 expression in 40 paired OC tissue samples and cell lines using real-time quantitative reverse transcription polymerase chain reaction and immunohistochemistry. Colony formation assays assessed proliferative capacity, while transwell assays measured invasive and migratory potential. Additionally, a tumor xenograft model in nude mice was employed to verify in vivo proliferative effects. Results: The results demonstrated that CNTN1 expression was markedly elevated in OC tissues and positively associated with advanced tumor stage, metastasis, and poor prognosis. Silencing CNTN1 significantly inhibited proliferation, migration, and invasion in OC cell lines. Bioinformatics analysis combined with luciferase assays identified a regulatory interaction between CNTN1 and presenilin-1 (PSEN1), with CNTN1 expression positively correlating with PSEN1 levels in patient samples. Notably, PSEN1 overexpression reversed the impaired proliferation, migration, and invasion induced by CNTN1 suppression. Conclusions: These findings suggest that CNTN1 promotes OC progression through PSEN1 regulation and may represent a prognostic biomarker for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.